REGENERON PHARMACEUTICALS
-
Regeneron beats quarterly results on strong demand for eczema, eye treatments
The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
-
Cencora raises annual profit forecast on strong demand for specialty medicines
-
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
-
Regeneron to defend against DOJ complaint on drug-price manipulation
-
Regeneron's blood cancer therapy faces setback as FDA raises trial concerns
-
Vertex non-opioid painkiller meets main goal in late-stage trials
-
Experimental gene therapy allows kids with inherited deafness to hear
-
US FDA expands use of Regeneron's cholesterol drug in young children
-
EXPLAINER-How worried should we be about the Omicron variant?
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
